SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I. international comparisons. BJU Int 2002; 90: 16273
  • 2
    American Cancer Society. Cancer Facts and Figures 2007. Available at: http://www.cancer.org/statistics/cff2000/selectedcancers.html#prostate. Accessed January 2007
  • 3
    Cancer Research UK. Available at: http://www.cancerresearchuk.org/aboutcancer/statistics/incidence?version=1. Accessed January 2007
  • 4
    National Institute for Health & Clinical Excellence. Guidance on Cancer Services – Improving Outcomes in Urological Cancers: the Manual, September 2002 Available at: http://www.nice.org.uk/guidance/csguc. Accessed January 2007
  • 5
    Hope RA, Longmore JM, McManus SK, Wood-Allum C eds, Oxford Handbook of Clinical Medicine, 4th edn. Oxford: Oxford University Press, 1998
  • 6
    British Association of Urological Surgeons. BAUS cancer registry – analysis of minimum data set for urological cancers. Chart 69, 42. London: BAUS, 2005
  • 7
    Amling CL, Blute ML, Bergstralh EJ et al. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 2000; 164: 1015
  • 8
    Bott SR, Birtle AJ, Taylor CJ, Kirby RS. Prostate cancer management: 2. An update on locally advanced and metastatic disease. Postgrad Med J 2003; 79: 6435
  • 9
    Zietman AL, Prince EA, Nakfoor BM, Park JJ. Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system. Int J Radiat Oncol Biol Phys 1997; 38: 106770
  • 10
    Joon DL, Hasegawa M, Sikes C et al. Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. Int J Radiat Oncol Biol Phys 1997; 38: 10717
  • 11
    Anonymous. Treatment and survival of patients with cancer of the prostate. Veterans Administration Cooperative Urological Research Group. Surg Gynecol Obstet 1967; 124: 10117
  • 12
    Byar DP. Treatment of prostate cancer: studies by the Veterans Administration Cooperative Urological Research Group. Bull NY Acad Med 1972; 48: 75166
  • 13
    Byar DP. VACURG studies on prostate cancer and its treatment. In TannenbaumM ed., Urological Pathology – the Prostate. Philadelphia: Lea & Febiger, 1977
  • 14
    Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr 1988; 7: 16570
  • 15
    Chalmers TC, Celano P, Sacks HS, Smith H Jr. Bias in treatment assignment in controlled clinical trials. N Engl J Med 1983; 309: 135861
  • 16
    Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 40812
  • 17
    Moher D, Pham B, Jones A et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998; 352: 60913
  • 18
    Petitti DB. Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine, 2nd edn. Oxford: Oxford University Press, 2000
  • 19
    Montreuil B, Bendavid Y, Brophy J. What is so odd about odds? Can J Surg 2005; 48: 4008
  • 20
    Egger M, Davey Smith G, Schneider, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 62934
  • 21
    StatsDirect Ltd. StatsDirect statistical software. http://www.statsdirect.com. UK: StatsDirectLtd, 2002. Accessed January 2007
  • 22
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 17788
  • 23
    Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. Br J Urol 1997; 79: 23546
  • 24
    Pilepich MV, Winter K, John MJ et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86–10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50: 124352
  • 25
    Bolla M, Collette L, Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 1036
  • 26
    Messing E, Manola J, Sarosdy M et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer: results at 10 years of EST 3886. J Urol 2003; 169 (Suppl. 4): 396, A1480
  • 27
    Denham JW, Steigler A, Lamb DS et al. Short-term androgen deprivation and radiotherapy for locally advanced cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005; 6: 84150
  • 28
    Iversen P, McLeod D, See W et al. Adding bicalutamide 150 mg to standard care for localised or locally advanced prostate cancer: results from the largest hormonal therapy trial ever conducted in prostate cancer patients, at over 7 years’ follow up. Abstract presented at the ECCO XIII meeting, October 2005
  • 29
    Pilepich MV, Winter K, Lawton CA et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma – long-term results of phase III RTOG 85–31. Int J Radiat Oncol Biol Phys 2005; 61: 128590
  • 30
    Studer UE, Whelan P, Albrecht W et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent. European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 2006; 24: 186876
  • 31
    White SJ, Freedman LS. Allocation of patients to treatment groups in a controlled clinical study. Br J Cancer 1978; 37: 84957
  • 32
    Zelen M. The randomisation and stratification of patients to clinical trials. J Chronic Dis 1974; 27: 36575
  • 33
    Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975; 31: 10315
  • 34
    Messing EM, Manola J, Sarosdy M et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. New Engl J Med 1999; 341: 17818
  • 35
    Tyrrell CJ, Payne H, See WA et al. Bicalutamide (‘Casodex’) 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. Radiother Oncol 2005; 76: 410
  • 36
    Hanks GE, Pajak TF, Porter A et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group protocol 92–02. J Clin Oncol 2003; 21: 39728
  • 37
    Messing EM, Manola J, Yao J et al.; Eastern Cooperative Oncology Group Study EST 3886. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006; 7: 4729
  • 38
    Wilt T, Nair B, MacDonald R, Rutks I. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev 2002; 1: CD003506. DOI 10.1002/14651858